THU0280 Extended Follow-Up of the Cyclofa-Lune Trial Comparing Two Sequential Induction and Maintenance Treatment Regimens for Proliferative Lupus Nephritis Based Either on Cyclophosphamide or Cyclosporine a. (23rd January 2014)

• Record Type: Journal Article
• Authors: Zavada, J.; Pesickova, S. S.; Rysava, R.; Horak, P.; Hrncir, Z.; Lukac, J.; Rovensky, J.; Vitova, J.; Bohmova, J.; Havrda, M.; Tegzova, D.; Olejarova, M.; Tesar, V.
• Is Part Of: Annals of the rheumatic diseases. Volume 72:Supplement 3(2013)
• Page Start: A260
• Page End: A260
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-eular.808
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: In the investigator-initiated prospective trial CYLOFA-LUNE [1 ] we tested the hypothesis that immunosuppressive regimen based on Cyclosporine A (CYA) may have similar efficacy but greater safety than that based on cyclophosphamide (CPH). Lupus patients with biopsy-proven proliferative glomerulonephritis were randomly assigned to a treatment protocol based on either CyA or CPH. Objectives: The main purpose of the current analysis was to ascertain the long-term renal outcome of patients randomised in the CYCLOFA-LUNE trial. Methods: Data for kidney function, and adverse events (death, cardiovascular event, tumor, premature menopause) were collected by a cross-sectional suvey for 38 of 40 patients initially randomised in the CYCLOFA-LUNE trial Results: The median follow-up time was 7.7 years (range 5.0-10.3). Rates of renal impairment and end-stage renal disease, adverse events (death, cardiovascular event, tumor, premature menopause) did not differ between the CPH and CyA group, nor did mean serum creatinine, 24 h proteinuria and SLICC damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents, and blood pressure lowering drugs. Conclusions: The data confirm that both regimens based either on CPH or CyA achieved good and similar clinical results in the very long term References: Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010 Oct;19(11):1281-9 Acknowledgements: Supported by the project (Ministry of Health, Czech Republic) MZO 00023728. Disclosure of Interest: None Declared